Germany has backed away from a plan to implement variable discount pricing on branded drugs after industry pushback, Reuters reports. The earlier proposal was part of healthcare reform efforts aimed at reducing drug spending, with staged markdown requirements for health insurers. Instead of a variable structure, the government will pursue a fixed discount plan, though specific details were not yet provided. The shift comes amid signals from major pharma leaders—including warnings about reducing planned investment in Germany under the original variable discount proposal. The policy reversal may reduce near-term pricing risk for manufacturers and influence future product launch strategies across the German market, one of Europe’s faster reimbursement environments.